P N Mobit1,2, S Packianathan1, R He1, C C Yang1. 1. 1 Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA. 2. 2 Cameroon Oncology Center, PO Box 1870, Douala, Cameroon.
Abstract
OBJECTIVE: To evaluate the dosimetric differences and similarities between treatment plans generated with Axxent-Xoft electronic brachytherapy source (Xoft-EBS), (192)Ir and (60)Co for tandem and ovoids (T&O) applicators. METHODS: In this retrospective study, we replanned 10 patients previously treated with (192)Ir high-dose-rate brachytherapy. Prescription was 7 Gy × 4 fractions to Point A. For each original plan, we created two additional plans with Xoft-EBS and (60)Co. The dose to each organ at risk (OAR) was evaluated in terms of V(35%) and V(50%), the percentage volume receiving 35% and 50% of the prescription dose, respectively, and D(2cc), highest dose to a 2 cm(3) volume of an OAR. RESULTS: There was no difference between plans generated by (192)Ir and (60)Co, but the plans generated using Xoft-EBS showed a reduction of up to 50% in V(35%), V(50%) and D(2cc). The volumes of the 200% and 150% isodose lines, however, were 74% and 34% greater than the comparable volumes generated with the (192)Ir source. Point B dose was on average only 16% of the Point A dose for plans generated with Xoft-EBS compared with 30% for plans generated with (192)Ir or (60)Co. CONCLUSION: The Xoft-EBS can potentially replace either (192)Ir or (60)Co in T&O treatments. Xoft-EBS offers either better sparing of the OARs compared with (192)Ir or (60)Co or at least similar sparing. Xoft-EBS-generated plans had higher doses within the target volume than (192)Ir- or (60)Co-generated ones. ADVANCES IN KNOWLEDGE: This work presents newer knowledge in dosimetric comparison between Xoft-EBS, (192)Ir or (60)Co sources for T&O implants.
OBJECTIVE: To evaluate the dosimetric differences and similarities between treatment plans generated with Axxent-Xoft electronic brachytherapy source (Xoft-EBS), (192)Ir and (60)Co for tandem and ovoids (T&O) applicators. METHODS: In this retrospective study, we replanned 10 patients previously treated with (192)Ir high-dose-rate brachytherapy. Prescription was 7 Gy × 4 fractions to Point A. For each original plan, we created two additional plans with Xoft-EBS and (60)Co. The dose to each organ at risk (OAR) was evaluated in terms of V(35%) and V(50%), the percentage volume receiving 35% and 50% of the prescription dose, respectively, and D(2cc), highest dose to a 2 cm(3) volume of an OAR. RESULTS: There was no difference between plans generated by (192)Ir and (60)Co, but the plans generated using Xoft-EBS showed a reduction of up to 50% in V(35%), V(50%) and D(2cc). The volumes of the 200% and 150% isodose lines, however, were 74% and 34% greater than the comparable volumes generated with the (192)Ir source. Point B dose was on average only 16% of the Point A dose for plans generated with Xoft-EBS compared with 30% for plans generated with (192)Ir or (60)Co. CONCLUSION: The Xoft-EBS can potentially replace either (192)Ir or (60)Co in T&O treatments. Xoft-EBS offers either better sparing of the OARs compared with (192)Ir or (60)Co or at least similar sparing. Xoft-EBS-generated plans had higher doses within the target volume than (192)Ir- or (60)Co-generated ones. ADVANCES IN KNOWLEDGE: This work presents newer knowledge in dosimetric comparison between Xoft-EBS, (192)Ir or (60)Co sources for T&O implants.
Authors: Richard Pötter; Christine Haie-Meder; Erik Van Limbergen; Isabelle Barillot; Marisol De Brabandere; Johannes Dimopoulos; Isabelle Dumas; Beth Erickson; Stefan Lang; An Nulens; Peter Petrow; Jason Rownd; Christian Kirisits Journal: Radiother Oncol Date: 2006-01-05 Impact factor: 6.280
Authors: Adam Dickler; Michael C Kirk; Neil Seif; Katherine Griem; Kambiz Dowlatshahi; Darius Francescatti; Ross A Abrams Journal: Brachytherapy Date: 2007 Apr-Jun Impact factor: 2.362
Authors: Paul N Mobit; Priyadarshini Rajaguru; Michael Brewer; Michael Baird; Satyaseelan Packianathan; Claus Chunli Yang Journal: Radiat Prot Dosimetry Date: 2014-09-28 Impact factor: 0.972
Authors: Elizabeth Falkenberg; Robert Y Kim; Sreelatha Meleth; Jennifer De Los Santos; Sharon Spencer Journal: Brachytherapy Date: 2006 Jan-Mar Impact factor: 2.362
Authors: Adam Dickler; Michael C Kirk; Alan Coon; Damian Bernard; Tom Zusag; Jacob Rotmensch; David E Wazer Journal: Brachytherapy Date: 2008-09-09 Impact factor: 2.362
Authors: Arne Mathias Ruder; Laurens Inghelram; Frank Schneider; Gustavo R Sarria; Jürgen Hesser; Frederic Bludau; Udo Obertacke; Frederik Wenz; Yasser Abo-Madyan; Frank A Giordano Journal: J Contemp Brachytherapy Date: 2020-10-30